Navigation Links
Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
Date:2/23/2011

HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to discuss the analytical method of the upcoming VISTA-16 interim biomarker analysis and the expected timeline of the results.Conference Call Access:Date:

February 28, 2011Time:

5:00 pm Eastern TimeDomestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

45608522To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291.  The conference ID for the replay is 45608522. The audio replay will be available until March 7, 2011.  This conference call will be webcast live and archived on Anthera's website until February 28, 2012, www.anthera.com.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more informat
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 3, 2015 Redwood Pharma AB ... Co., Ltd., operating in both the US and ... IntelliGel ® supramolecular hydrogel technology in its lead ... ophthalmic therapies. The Broda technology offers many unique competitive ... free-forming liquid and with low concentrations of polymer the ...
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... TX and VANCOUVER , July ... "Company") (TSX-V: EPI) announced today that its common shares have ... Market ("NASDAQ") under the symbol "EPIX". ESSA will ... will retain its listing on the TSX Venture Exchange under ... listing of the common shares on the NASDAQ, each of ...
Breaking Medicine Technology:Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4
... Aug. 10, 2011 Aprima Medical Software announced today ... provider of Revenue Cycle Management (RCM) services to physician ... gains in receivables collection rates and days sales outstanding ... a 20% improvement in DSOs vs. industry standards. ...
... August 10, 2011 Agendia, a commercial-stage ... St. Gallen International Breast Cancer Conference (2011) Expert Panel,s ... patients by the particular biological subtype of their tumor ... According to the panel, "it is no longer tenable ...
Cached Medicine Technology:Aprima and Health Care Strategies Join Forces to Improve the Financial Health of Physicians 2Aprima and Health Care Strategies Join Forces to Improve the Financial Health of Physicians 3International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 2International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment 3
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, ... of technical sales expertise from the North American Board of Certified Energy Practitioners ... the most highly respected and well established national certification organization for renewable energy ...
(Date:7/3/2015)... ... 03, 2015 , ... On June 30th SEO authority and ... system called "Page One Engine" . The program, which has been hailed ... from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an ...
(Date:7/3/2015)... ... July 03, 2015 , ... Renowned rhinoplasty surgeon ... for the 2016 Dallas Rhinoplasty Symposium . To be held from March 4th ... will be held at the Westin Galleria Dallas. , Designed to take participants from ...
(Date:7/3/2015)... ... 2015 , ... The Erie County Bar Association Institute of ... Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... these types of cases. , Each year, New York State residents are hospitalized ...
(Date:7/3/2015)... ... ... Jennifer Renee Hanes, DO is the new Medical Director of its Sienna ... freestanding emergency rooms in the United States. , “We are excited to welcome Dr. ... Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. , Dr. ...
Breaking Medicine News(10 mins):Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3
... in people with diabetes than in those without the ... of Archives of Ophthalmology , one of the ... Americans had diagnosed diabetes mellitus in 2005 and another ... in the article. It is estimated that the number ...
... Oct. 13 As the first-ever report,by the United ... presented to Member States today, the Campaign to End,Fistula ... it serves.,According to its annual report, the campaign now ... in Africa, Asia and the Arab States. When it,was ...
... the Chargers Points to Myo-Med for Injury Recovery, ... Tomlinson points to Myo-Med ( http://www.myomed.com ) as,a key ... the Patriots,Tomlinson became the 17th player in NFL history ... times Sunday, a feat unexpected by critics who,thought his ...
... than Alzheimer,s patients, healthy controls , , MONDAY, Oct. 13 ... than healthy people or Alzheimer,s patients to have vitamin ... of Medicine in Atlanta. , They compared vitamin D ... 99 healthy people matched for age and other factors. ...
... N.J., Oct. 13, 2008 The AMERIGROUP Foundation,today ... for Children with,Hidden Intelligence (SCHI) to enhance the ... private school that specifically educates,multiply handicapped, underprivileged children ... is to try and alleviate the suffering of ...
... System, Supports Global Pharma Client in Closing ... CHESTER, Pa., Oct. 13 Modevity, LLC announced,today ... Imperium technology to become the primary platform for ... for their new product video content. Imperium is ...
Cached Medicine News:Health News:Vision loss more common in people with diabetes 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 2Health News:Campaign to End Fistula Quadruples In Size, Reaching Over 45 Countries, Says New Report 3Health News:Tomlinson Attributes Rebound to Anti-Inflammatory Cream 2Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:AMERIGROUP Foundation Supports the School for Children with Hidden Intelligence 2Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: